The Chinese drug maker Sinopharm has finally published the interim results from a phase 3 trial of its Covid-19 vaccine after more than 200 million doses have been administered worldwide. The study, published in the Journal of the American Medical Association on Wednesday, has finally answered
Follow RT on A study published in an American medical journal has shown that Sinopharm’s two jabs are 72.8% and 78.1% effective at preventing symptomatic Covid-19, but says there is insufficient trial data from elderly and vulnerable groups.
The study, published in the Journal of the American Medical Association on Wednesday, shows the two Chinese-made shots to be more effective than the World Health Organization (WHO) minimum requirement of 50% efficacy. The study references interim data from phase-3 trials involving 40,832 volunteers from across the UAE, Bahrain, Egypt and Jordan.
The published data answers scientists’ calls for greater transparency about the shots that have been administered more than 200 million times around the world.
The global tally of confirmed cases of COVID-19 rose above 168 million on Thursday, as China hit back at President Joe Biden's push to have U.S. intelligence investigate the origins of the coronavirus, amid renewed concerns it may have come from a laboratory in Wuhan.
Rejecting Rockefeller Germ Theory Once and for All lewrockwell.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lewrockwell.com Daily Mail and Mail on Sunday newspapers.
A new study has found that neither vitamin D nor the omega-3 fatty acids found in fish oil prevent the development of atrial fibrillation, a potentially serious heart rhythm disturbance, researchers at Cedars-Sinai Medical Center announced today.